{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-004157","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.643640+00:00","generated_at":"2026-05-26T22:12:15.180243+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Grace Therapeutics Q3 net loss $4.2M; Phase 3 STRIVE-ON meets endpoint; $15M placement","bullets":["Net loss $4.2M ($0.36/sh) vs $2.4M ($0.21/sh) YoY; R&D $2.2M up from $1.4M on GTx-104 trial.","Phase 3 STRIVE-ON safety trial met primary endpoint; NDA for GTx-104 anticipated H1 2025.","Secured $15M upfront private placement (Nantahala Capital, ADAR1, Stonepine); up to $15M additional from warrant exercises.","Cash at Dec 31, 2024: $11.1M, down from $23.0M at Mar 31, 2024.","FDA provided guidance on single pivotal trial design for GTx-102 (Ataxia-Telangiectasia) toward NDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-004157","json":"https://secwatch.observer/filing/0001140361-25-004157.json","markdown":"https://secwatch.observer/filing/0001140361-25-004157.md","text":"https://secwatch.observer/filing/0001140361-25-004157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125004157/0001140361-25-004157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125004157/ef20043203_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:12:15.180243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}